ByHeart Infant Formula MDL Consolidation (2026)

This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →

## ByHeart Infant Formula MDL Consolidation (2026) ### Overview The Judicial Panel on Multidistrict Litigation (JPML) has consolidated 19 class action lawsuits filed against ByHeart Inc. into a new multidistrict litigation (MDL) in New York federal court (Top Class Actions, April 2026). ByHeart is a premium infant formula brand that markets itself as using whole proteins and cleaner ingredients. ### MDL Details - **Number of cases consolidated**: 19 class action lawsuits (Top Class Actions, April 2026) - **Venue**: New York federal court (Top Class Actions, April 2026) - **Consolidating body**: Judicial Panel on Multidistrict Litigation (JPML) (Top Class Actions, April 2026) ### Alleged Claims While the source does not detail specific allegations, infant formula MDLs typically involve claims of: - Mislabeling or false advertising regarding nutritional content or ingredient quality - Failure to warn regarding contamination risks - Breach of warranty - Consumer protection statute violations (state UDAP claims) ### Legal Significance MDL consolidation signals that plaintiffs' counsel view the litigation as having sufficient scale and common factual questions to warrant coordinated pre-trial proceedings. The New York venue will subject ByHeart to discovery coordination and likely early bellwether trial selection. **Comparison**: The infant formula MDL landscape has been active following the Mead Johnson/Abbott NEC (necrotizing enterocolitis) litigation wave. The ByHeart MDL may reflect a distinct theory—likely marketing/labeling rather than NEC—but will benefit from established MDL infrastructure. ### Strategic Significance - ByHeart's premium market positioning and investor backing make it a high-profile defendant - MDL consolidation typically accelerates settlement pressure on smaller defendants - Outcome may affect labeling standards across the premium infant formula market - Relevant to FDA regulatory posture on infant formula claims post-2022 shortage crisis ### Anticipated Developments - Appointment of Plaintiffs' Steering Committee - Initial case management conference and scheduling order - Motion practice on class certification and Daubert challenges - Potential early settlement discussions